Manuel M Garrido1,2, Ruy M Ribeiro3, Kimberly Krüger4, Luís C Pinheiro5,6, João T Guimarães7,8,9, Stefan Holdenrieder4. 1. Department of Clinical Pathology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal; manuel.agarrido@chlc.min-saude.pt. 2. Department of Laboratory Medicine, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal. 3. Biomathematics Laboratory, Faculdade de Medicina da Universidade de Lisboa, Lisbon, Portugal. 4. Institute of Laboratory Medicine, Munich Biomarker Research Center, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. 5. Department of Urology, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal. 6. Department of Urology, Faculdade de Ciências Médicas da Universidade Nova de Lisboa, Lisbon, Portugal. 7. Department of Clinical Pathology, Centro Hospitalar Universitário de São João, Porto, Portugal. 8. Department of Biomedicine, Faculdade de Medicina, Universidade do Porto, Porto, Portugal. 9. EPIUnit, Instituto de Saúde Pública, Universidade do Porto, Porto, Portugal.
Abstract
BACKGROUND/AIM: Evasion from cell death occurs in prostate cancer (PCa). We verified whether serum levels of cell death markers can have diagnostic value in PCa. PATIENTS AND METHODS: A total of 233 men scheduled for prostate biopsy [prostate specific antigen (PSA) level: 2-10 ng/ml] were enrolled. Serum nucleosomes, nucleosomes containing the H3 histone (H3), high mobility group box 1 (HMGB1), and soluble receptor for advanced glycation end products (sRAGE) were analyzed by enzyme immunoassays. RESULTS: There were no differences (p>0.05) in nucleosomes, H3, and sRAGE levels between patients with and without PCa or clinically significant PCa (csPCa). HMGB1 had lower levels in PCa patients (p=0.023) and was a predictor of PCa (p=0.047), but not of csPCa (p=0.180). CONCLUSION: In patients with critical PSA levels between 2-10 ng/ml, HMGB1 had some diagnostic value for overall PCa detection, but it was not predictive of csPCa. Nucleosomes, H3 and sRAGE did not discriminate between PCa or csPCa and controls.
BACKGROUND/AIM: Evasion from cell death occurs in prostate cancer (PCa). We verified whether serum levels of cell death markers can have diagnostic value in PCa. PATIENTS AND METHODS: A total of 233 men scheduled for prostate biopsy [prostate specific antigen (PSA) level: 2-10 ng/ml] were enrolled. Serum nucleosomes, nucleosomes containing the H3 histone (H3), high mobility group box 1 (HMGB1), and soluble receptor for advanced glycation end products (sRAGE) were analyzed by enzyme immunoassays. RESULTS: There were no differences (p>0.05) in nucleosomes, H3, and sRAGE levels between patients with and without PCa or clinically significant PCa (csPCa). HMGB1 had lower levels in PCa patients (p=0.023) and was a predictor of PCa (p=0.047), but not of csPCa (p=0.180). CONCLUSION: In patients with critical PSA levels between 2-10 ng/ml, HMGB1 had some diagnostic value for overall PCa detection, but it was not predictive of csPCa. Nucleosomes, H3 and sRAGE did not discriminate between PCa or csPCa and controls.
Authors: Meelan Bul; Xiaoye Zhu; Riccardo Valdagni; Tom Pickles; Yoshiyuki Kakehi; Antti Rannikko; Anders Bjartell; Deric K van der Schoot; Erik B Cornel; Giario N Conti; Egbert R Boevé; Frédéric Staerman; Jenneke J Vis-Maters; Henk Vergunst; Joris J Jaspars; Petra Strölin; Erik van Muilekom; Fritz H Schröder; Chris H Bangma; Monique J Roobol Journal: Eur Urol Date: 2012-11-12 Impact factor: 20.096
Authors: Yvonne Nadine Fahmueller; Dorothea Nagel; Ralf-Thorsten Hoffmann; Klaus Tatsch; Tobias Jakobs; Petra Stieber; Stefan Holdenrieder Journal: Int J Cancer Date: 2013-01-18 Impact factor: 7.396